The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in mice
Nowadays, vaccines are broadly used to prevent porcine circovirus type 2 (PCV2) infection-induced expenditures, but the virus is still spreading among pigs. The current PCV2 vaccines all rely on the immunogenicity of Cap, yet our previous studies found that Cap is also the major component mediating...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2022.1077026/full |
| _version_ | 1828067207034175488 |
|---|---|
| author | Qian Du Qian Du Tengfei Shi Tengfei Shi Huaxin Wang Huaxin Wang Changlei Zhu Changlei Zhu Nan Yang Nan Yang Dewen Tong Dewen Tong Yong Huang Yong Huang |
| author_facet | Qian Du Qian Du Tengfei Shi Tengfei Shi Huaxin Wang Huaxin Wang Changlei Zhu Changlei Zhu Nan Yang Nan Yang Dewen Tong Dewen Tong Yong Huang Yong Huang |
| author_sort | Qian Du |
| collection | DOAJ |
| description | Nowadays, vaccines are broadly used to prevent porcine circovirus type 2 (PCV2) infection-induced expenditures, but the virus is still spreading among pigs. The current PCV2 vaccines all rely on the immunogenicity of Cap, yet our previous studies found that Cap is also the major component mediating the PCV2 infection-induced immune suppression through its interaction with host gC1qR. Thereby, new vaccines are still necessary for PCV2 prevention and control. In this study, we constructed a new PCV2 DNA vaccine expressing the gC1qR binding site mutant Cap. We introduced the Intron A and WPRE elements into the vector to improve the Cap expression level, and fused the IL-2 secretory signal peptides to the N-terminal of Cap to mediate the secretion of Cap. We also screened and selected chemokines CXCL12, CCL22, and CCL25 to migrate dendritic cells. In addition, we contained the vectors with PEI and then ultrasonic them into nano size to enhance the entrance of the vectors. Finally, the animal experiments showed that the new PCV2 DNA vaccine expressing the gC1qR binding site mutant Cap could induce stronger humoral and cellular immune responses than the PCV2 DNA vaccine expressing the wild-type Cap and the non-ultrasonic treated PCV2 DNA vaccine in mice, and protect the mice from PCV2 infection and lung lesions. The results indicate the new PCV2 DNA vaccine expressing the gC1qR binding site mutant Cap has a certain development value, and provide new insight into the development of novel PCV2 vaccines. |
| first_indexed | 2024-04-10T23:42:44Z |
| format | Article |
| id | doaj.art-82a87545c9de435aa4826b175468995e |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-04-10T23:42:44Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-82a87545c9de435aa4826b175468995e2023-01-11T05:47:31ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2023-01-011310.3389/fmicb.2022.10770261077026The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in miceQian Du0Qian Du1Tengfei Shi2Tengfei Shi3Huaxin Wang4Huaxin Wang5Changlei Zhu6Changlei Zhu7Nan Yang8Nan Yang9Dewen Tong10Dewen Tong11Yong Huang12Yong Huang13College of Veterinary Medicine, Northwest A&F University, Xianyang, ChinaEngineering Research Center of Efficient New Vaccines for Animals, Ministry of Education, Xianyang, ChinaCollege of Veterinary Medicine, Northwest A&F University, Xianyang, ChinaEngineering Research Center of Efficient New Vaccines for Animals, Ministry of Education, Xianyang, ChinaCollege of Veterinary Medicine, Northwest A&F University, Xianyang, ChinaEngineering Research Center of Efficient New Vaccines for Animals, Ministry of Education, Xianyang, ChinaCollege of Veterinary Medicine, Northwest A&F University, Xianyang, ChinaEngineering Research Center of Efficient New Vaccines for Animals, Ministry of Education, Xianyang, ChinaCollege of Veterinary Medicine, Northwest A&F University, Xianyang, ChinaEngineering Research Center of Efficient New Vaccines for Animals, Ministry of Education, Xianyang, ChinaCollege of Veterinary Medicine, Northwest A&F University, Xianyang, ChinaEngineering Research Center of Efficient New Vaccines for Animals, Ministry of Education, Xianyang, ChinaCollege of Veterinary Medicine, Northwest A&F University, Xianyang, ChinaEngineering Research Center of Efficient New Vaccines for Animals, Ministry of Education, Xianyang, ChinaNowadays, vaccines are broadly used to prevent porcine circovirus type 2 (PCV2) infection-induced expenditures, but the virus is still spreading among pigs. The current PCV2 vaccines all rely on the immunogenicity of Cap, yet our previous studies found that Cap is also the major component mediating the PCV2 infection-induced immune suppression through its interaction with host gC1qR. Thereby, new vaccines are still necessary for PCV2 prevention and control. In this study, we constructed a new PCV2 DNA vaccine expressing the gC1qR binding site mutant Cap. We introduced the Intron A and WPRE elements into the vector to improve the Cap expression level, and fused the IL-2 secretory signal peptides to the N-terminal of Cap to mediate the secretion of Cap. We also screened and selected chemokines CXCL12, CCL22, and CCL25 to migrate dendritic cells. In addition, we contained the vectors with PEI and then ultrasonic them into nano size to enhance the entrance of the vectors. Finally, the animal experiments showed that the new PCV2 DNA vaccine expressing the gC1qR binding site mutant Cap could induce stronger humoral and cellular immune responses than the PCV2 DNA vaccine expressing the wild-type Cap and the non-ultrasonic treated PCV2 DNA vaccine in mice, and protect the mice from PCV2 infection and lung lesions. The results indicate the new PCV2 DNA vaccine expressing the gC1qR binding site mutant Cap has a certain development value, and provide new insight into the development of novel PCV2 vaccines.https://www.frontiersin.org/articles/10.3389/fmicb.2022.1077026/fullporcine circovirus type 2DNA vaccinegC1qR binding site mutant Capexpression enhancementnanoliposome |
| spellingShingle | Qian Du Qian Du Tengfei Shi Tengfei Shi Huaxin Wang Huaxin Wang Changlei Zhu Changlei Zhu Nan Yang Nan Yang Dewen Tong Dewen Tong Yong Huang Yong Huang The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in mice Frontiers in Microbiology porcine circovirus type 2 DNA vaccine gC1qR binding site mutant Cap expression enhancement nanoliposome |
| title | The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in mice |
| title_full | The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in mice |
| title_fullStr | The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in mice |
| title_full_unstemmed | The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in mice |
| title_short | The ultrasonically treated nanoliposomes containing PCV2 DNA vaccine expressing gC1qR binding site mutant Cap is efficient in mice |
| title_sort | ultrasonically treated nanoliposomes containing pcv2 dna vaccine expressing gc1qr binding site mutant cap is efficient in mice |
| topic | porcine circovirus type 2 DNA vaccine gC1qR binding site mutant Cap expression enhancement nanoliposome |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2022.1077026/full |
| work_keys_str_mv | AT qiandu theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT qiandu theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT tengfeishi theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT tengfeishi theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT huaxinwang theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT huaxinwang theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT changleizhu theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT changleizhu theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT nanyang theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT nanyang theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT dewentong theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT dewentong theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT yonghuang theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT yonghuang theultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT qiandu ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT qiandu ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT tengfeishi ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT tengfeishi ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT huaxinwang ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT huaxinwang ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT changleizhu ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT changleizhu ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT nanyang ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT nanyang ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT dewentong ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT dewentong ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT yonghuang ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice AT yonghuang ultrasonicallytreatednanoliposomescontainingpcv2dnavaccineexpressinggc1qrbindingsitemutantcapisefficientinmice |